Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30950592 | 1.00 | ASIC3 (0.47) | ASIC3DRD2DRD3PNMTHTR2C | |
| SCHEMBL11334101 | 0.92 | PNMT (0.47) | DRD2DRD3PNMTMELKADRA2A | |
| SCHEMBL330372 | 0.88 | ASIC3 (0.60) | ASIC3DRD2DRD3PNMTHTR2C | |
| Hydrochloric Acid SCHEMBL1000880 | 0.86 | ASIC3 (0.58) | ASIC3DRD2DRD3PNMTHTR2C | |
| SCHEMBL29741628 | 0.80 | PNMT (0.60) | DRD2DRD3PNMTHTR2CHTR2A | |
| SCHEMBL420370 | 0.80 | PNMT (0.60) | DRD2DRD3PNMTHTR2CHTR2A | |
| SCHEMBL107103 | 0.79 | CYP1A2 (0.43) | ASIC3PNMTHTR2CHTR2APARP1 | |
| SCHEMBL14704881 | 0.78 | ASIC3 (0.48) | ASIC3DRD2DRD3PNMTCD44 | |
| Hydrochloric Acid SCHEMBL29586555 | 0.78 | PNMT (0.58) | DRD2DRD3PNMTHTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL999244 | 0.78 | PNMT (0.58) | DRD2DRD3PNMTHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317689-A1 | POTASSIUM CHANNEL MODULATOR, COMPOSITION AND APPLICATION | NEUSHEN THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2024-09-26 | — | — | US | disclosed |
| EP-4393907-A1 | POTASSIUM CHANNEL MODULATOR, COMPOSITION AND APPLICATION | Neushen Therapeutics (Shanghai) Co., Ltd (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-115724799-A | Potassium channel regulator, composition and application | 杭州和正医药有限公司 | 2023-03-03 | — | — | CN | disclosed |
| WO-2023025276-A1 | POTASSIUM CHANNEL MODULATOR, COMPOSITION AND APPLICATION | 杭州和正医药有限公司 | 2023-03-02 | — | — | WO | disclosed |
| US-7947833-B2 | methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | ALLISON BRETT D | 2008-03-27 | — | — | US | disclosed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7288651-B2 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| EP-1651622-B1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1651622-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651621-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005016897-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016896-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317689-A1 | POTASSIUM CHANNEL MODULATOR, COMPOSITION AND APPLICATION | KCNQ3, KCNQ1, KCNQ2 | ASIC3 104/4885DRD2 2521/4885DRD3 1693/4885 |
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | ASIC3 1979/4885DRD2 1287/4885DRD3 2257/4885 |
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | ASIC3 1979/4885DRD2 1287/4885DRD3 2257/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | ASIC3 1184/4885DRD2 3370/4885DRD3 4301/4885 |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | ASIC3 1184/4885DRD2 3370/4885DRD3 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.